Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 7Thoracic 1Plasma cell 1Dermatologic 1

Conditions

Melanoma 68Skin Neoplasms 15Neoplasm Metastasis 14Lymphoma, T-Cell, Cutaneous 9Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 8Neoplasms 7Lymphoma 7Ovarian Neoplasms 6Mycosis Fungoides 6Kidney Neoplasms 6Colorectal Neoplasms 6Carcinoma, Merkel Cell 6Uveal Melanoma 5Uterine Cervical Neoplasms 5Sezary Syndrome 5Multiple Myeloma 5Esophageal Neoplasms 5Carcinoma, Hepatocellular 5Stomach Neoplasms 4Sarcoma, Synovial 4Pancreatic Neoplasms 4Lung Neoplasms 4Head and Neck Neoplasms 4Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Lymphoma, Non-Hodgkin 3

Interventions

Cyclophosphamide 2pembrolizumab 1fludarabine 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma, Myxoid × fludarabine × Dermatologic × Clear all
NCT03399448 2023-06-22

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

University of Pennsylvania

Phase 1 Terminated
3 enrolled
DermatologicPlasma cellSarcoma

Melanoma, Multiple Myeloma, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡